Get to know one of the Editors behind Bioanalysis Zone 🎤 Sneak peak of our upcoming partnership with the hosts of the BioTalk Unzipped podcast! A bit of a different one this time...our Editor Emma will be interviewed behind the camera! We love a good uno reverse card 🔄 Host Gregory Austin asks Emma about her background and journey working at Bioanalysis Zone, as well as upcoming industry trends she's excited about. We'll be publishing the interview on Bioanalysis Zone and on BioTalk Unzipped, so stay tuned... 👀

Millions of women worldwide face barriers to routine cervical cancer screening, but a new partnership between Waters Corporation and Quest Diagnostics aims to make testing more accessible through at-home sample collection. Find out more about the test and how to access it here: hubs.ly/Q04BWmfx0

Don’t miss our next webinar with BioAgilytix, ‘Streamlined preclinical bioanalytical strategies: accelerate time to IND.’ Register now >>> hubs.ly/Q04zwwVC0

There’s just ONE WEEK LEFT to complete our survey on biomarkers in bioanalysis.   Enter our #PrizeDraw to win a USD $100 voucher. The survey ends October 29, 2026, so don’t miss out! >>> hubs.ly/Q04zg4LX0

An empowering and fascinating opening plenary at #PharmSci360 from Julie Gerberding, President and Chief Executive Officer of the Foundation for the National Institutes of Health! A quick summary for those who missed it: ⭐ AI's role in drug discovery is still early, we don't yet know if it will outperform conventional discovery. ⭐ We have to modernize preclinical assessment, and that's where the FDA are backing new approach methodologies. ⭐ It's important to focus on end-to-end patient participation in clinical trials, not as an after thought. New awards are recognizing this value, such as the inaugural 2026 Prix Galien USA Patient First Award, which will be presented soon! ⭐ There is an increasing emphasis on defining both valid and qualified (context-of-use) biomarkers. Looking ahead, biomedical innovation will involve integrating novel alternative methods, AI, adaptive trial advancements, and other emerging techniques to enhance both the efficiency and safety of translational medicine. What were your thoughts on the talk? Comment below 👇

❔What's on your #PharmSci360 agenda❔ Here are a few of the talks that we're looking forward to: 🔬 Immunogenicity risk assessment of novel modalities using NAMs, with Sharon Vijayanand 🔬 Rapid Fire: Pushing the boundaries of hybrid LC–MS bioanalysis, with Robert MacNeill (special shoutout!) 🔬 Hot topic: Immunogenicity expectations: are they fact or fear? with Susan Kirshner and Paramita Mookherjee 🔬 Bioanalytical strategies for antibody-oligonucleotide conjugates (AOCs) with Padmanabhan Eangoor 🔬 Symposium: Biomarker-to-decision: biomarker contexts of use and fit-for-purpose strategies with Amanda Hays as Moderator Which will you be attending?

We can’t wait to see many of you tomorrow at #PharmSci360 2026! We’ll be at booth 829 bright and early so stop by the booth to have a chat! 🌄 @aapscomms (hubs.ly/Q04BSkVz0)

It's almost time...🕑 We’re excited to be an official Media Partner of #PharmSci360! Keep your eyes peeled for exclusive interviews with conference presenters, plus our conference report highlighting some of the exciting talks taking place throughout the week!

Check out our 2-minute video on ‘Addressing ligand binding assay challenges in ADC analysis’ as part of our latest In the Zone with @GyrosProteinTec!  Watch now >>> hubs.ly/Q04z-PPg0

Successful #biomarker programs start with alignment 🤝   Whether you're an experienced Sponsor or new to biomarker assay development, collaboration between CROs and Sponsors is critical. This Spotlight shares both perspectives, revealing how clear communication, shared understanding of context of use, and integrated PK-biomarker strategies lead to faster timelines and better outcomes.  Find all of our resources here, in partnership with @Resolian_ >>> hubs.ly/Q04zg2fM0

How do you de-risk mRNA-LNP therapeutics? Our 4 November webinar covers integrated strategies for biodistribution, bioanalysis and safety assessment to help you make confident IND-enabling decisions. Register >>> hubs.ly/Q04BghNp0

⏱️ When should you assess immune responses for LNP products? The answer: throughout the entire development lifecycle!  From early discovery and formulation screening through to preclinical studies and clinical trials, a risk-based approach tailored to your product's mechanism of action and indication ensures comprehensive safety and efficacy evaluation.  Read more here >>> hubs.ly/Q04xMF-v0

On October 1, Immunologix Laboratories hosted the 3rd Annual Bioanalysis Symposium: The Science of Fit-For-Purpose Bioanalysis, at Le Méridien Boston Cambridge. The program spanned three sessions centered on a single question that ran through the day: how to design and validate bioanalytical strategies that answer the specific clinical question a therapeutic program needs to address, rather than defaulting to legacy assay conventions. Read our highlights from the event ⭐👉 Highlights from the 3rd Annual Immunologix Bioanalysis Symposium - Bioanalysis Zone (hubs.ly/Q04B_87q0)

This might be our biggest prize draw yet…  Complete our 5-min #survey and you could be in with the chance to win one of two UDS $100 vouchers.  Move quickly before it closes >>> hubs.ly/Q04zg4LY0

There’s just a few days to go before the BZ team head to #PharmSci360! Watch this space for our highlights from the event, including interviews with conference speakers📽️ We're so excited to meet you 👋

Read this Perspective: ‘Biomarker validation – where are we today?’ today!  Check out the Perspective, as part of our Spotlight with @Resolian_, here >>>  hubs.ly/Q04zq1ln0

What if you could reduce bioanalytical delays and speed up development timelines? Discover how leading CROs are doing it with connected, end-to-end workflows and digital technologies. Join us: hubs.ly/Q04Bdn860

Are decades-old immunogenicity testing paradigms still fit for today’s therapeutic landscape, or is it time for a more scientifically relevant, risk-based approach?  Read the #WhitePaper from @IQVIA_global to learn more about immunogenicity testing >>>   hubs.ly/Q04zf-zx0

Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the US Food and Drug Administration has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab), for the treatment of chronic inflammatory and autoimmune conditions ➡️ hubs.ly/Q04BSsNX0

Attending #PharmSci360 2026? The Bioanalysis Zone team will be at booth 829 to chat with you about the Bioanalysis journal and Digital Hub and how you can get involved with our content📘  Reach out to book a meeting with us >>> [email protected] Plus, as an official Media Partner, we will be filming content with conference speakers so be sure to stay tuned 👀📽️ @aapscomms